Last reviewed · How we verify

NCT06997562

Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

Completed NA Last updated 30 May 2025
What this trial tests

NA trial testing Greater occipital nerve blockade in Greater Occipital Nerve Block in 60 participants. Completed in 3 May 2025.

Timeline
1 May 2024
Primary endpoint
3 May 2025
3 May 2025

Quick facts

Lead sponsorNew Valley University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date1 May 2024
Primary completion3 May 2025
Estimated completion3 May 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

New Valley University

Who can join

Adults 18 to 65, any sex, with Greater Occipital Nerve Block or Sphenopalatine Ganglion Block. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Greater occipital nerve blockade

Trials testing the same drug.

Other recruiting trials for Greater Occipital Nerve Block

Currently open trials in the same condition.

Other New Valley University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06997562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing